Red light therapy, photobiomodulation, has been used in clinical practice to mitigate the adverse side effects usually associated with radiotherapy. However, no studies have explored its use as a radiosensitizer of TNBC. Here, we used TNBC-bearing mice as a radioresistant cance...
Scope of Policy This Clinical Policy Bulletin addresses negative pressure wound therapy. Medical Necessity Aetna considers negative pressure wound therapy (NPWT) pumps medically necessary, when either of the following criteria (A or B) is met: Ulcers and Wounds in the Home Setting The member has ...
The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as t
Previous researches have demonstrated the meaning of CTSB for the progress of several tumors, whereas few clues about its immunological characteristic in gliomas. Here we systematically explored its biologic features and clinical significance for gliomas
L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7, 392–397 (2007). 8. Mukherjee, A. & Martin, S. G. The thioredoxin system: a key target in tumour and endothelial cells. Br. J. Radiol. 81 Spec No 1, S57–S68 (2008). 9. Junn, E. et al. ...
We evaluate doxorubicin effects on TNBC cells, identifying GRP78 subpopulations linked to invasiveness. Specifically, we evaluate the motility and invasiveness of GRP78 positive vs. negative cell subpopulations by two different assays: the in vitro Boyden chamber migration assay and our innovative, ...
Another trial, OlympiA, evaluated the effectiveness and side effects of olaparib compared to placebo in the adjunctive therapy of patients with early-stage HER2-negative BC who carry the BRCA1/2 germline mutation. Results revealed that olaparib significantly improved patient OS compared to the placebo...
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the su
treatment strategies are effective to some extent, significant limitations such as medication accessibility to distant tumor cells, greater therapeutic doses, nonspecific targeting, uneven biodistribution, and undesired side effects limit the efficiency of current triple negative breast cancer therapy7. ...
Another trial, OlympiA, evaluated the effectiveness and side effects of olaparib compared to placebo in the adjunctive therapy of patients with early-stage HER2-negative BC who carry the BRCA1/2 germline mutation. Results revealed that olaparib significantly improved patient OS compared to the placebo...